CTX321 Trademark

Trademark Overview

On Wednesday, January 7, 2026, a trademark application was filed for CTX321 with the United States Patent and Trademark Office. The USPTO has given the CTX321 trademark a serial number of 99583004. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, January 7, 2026. This trademark is owned by CRISPR Therapeutics AG. The CTX321 trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy

Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy
ctx321

General Information

Serial Number99583004
Word MarkCTX321
Filing DateWednesday, January 7, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateWednesday, January 7, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesGene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
Goods and ServicesCells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 7, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, January 7, 2026
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCRISPR Therapeutics AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressZUG V8 6300
CH

Trademark Events

Event DateEvent Description
Wednesday, January 7, 2026NEW APPLICATION ENTERED
Wednesday, January 7, 2026APPLICATION FILING RECEIPT MAILED

Related Keywords

gene editing therapy field vivo treatment cardiovascular namely disease pharmaceutical